BioCentury
ARTICLE | Distillery Therapeutics

Cancer

June 28, 2018 5:50 PM UTC

Patient sample, cell culture and mouse studies suggest inhibiting ELP3 or CTU2 could help treat drug-resistant BRAF-mutant melanoma. In tumor samples from melanoma patients, high expression of genes regulating post-transcriptional tRNA modification, including ELP3 and CTU2, correlated with high expression of a gene signature associated with resistance to BRAF inhibitors. In three BRAF-mutant melanoma cell lines resistant to Zelboraf vemurafenib, Zelboraf plus knockout of ELP3 or CTU2 increased cell death compared with any of the strategies alone. In a xenograft mouse model of BRAF-mutant Zelboraf-resistant melanoma, Zelboraf plus tumor-specific shRNA-mediated knockdown of ELP3 or CTU2 decreased tumor growth. Next steps could include identifying inhibitors of ELP3 and CTU2 and testing them in mouse models of BRAF inhibitor-resistant melanoma...

BCIQ Company Profiles

University of Liege

BCIQ Target Profiles

BRAF